MedTrace Logo

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

NCT05101317 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-01-21

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.

Conditions

  • Endometriosis

Interventions

DRUG

Placebo

Placebo

DRUG

HMI-115

HMI-115 is human monoclonal antibody

Sponsors & Collaborators

  • Hope Medicine (Nanjing) Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-11
Primary Completion
2024-09-26
Completion
2025-03-19
FDA Drug
Yes

Countries

  • United States
  • China
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101317 on ClinicalTrials.gov